Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility
Giulia C. Kennedy(Veracyte (United States)), Mark P. Steele(Vanderbilt University), David A. Lynch(McMaster University), Kevin K. Brown(Health Protection Surveillance Centre), Jeffrey L. Myers(University of Michigan), P. Sean Walsh(Veracyte (United States)), Thomas V. Colby(Mayo Clinic in Arizona), Grazyna Fedorowicz(Veracyte (United States)), Neil M. Barth(Veracyte (United States)), Jing Huang(Veracyte (United States)), Fernando J. Martínez(University of Massachusetts Chan Medical School), Jessica Anderson(Veracyte (United States)), Daniel G. Pankratz(Veracyte (United States)), Yoonha Choi(Ewha Womans University), Steve D. Groshong(National Jewish Health), Ganesh Raghu(University of Washington)
Cited by 0
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k